The highest incidence of meningococcal disease occurs in infants younger than 1 year of age.
loss, and neurodevelopmental disabilities [1, 2] . Even in the absence of epidemics, more than 500,000 cases of invasive meningococcal disease (IMD) occur annually worldwide of which approximately 50,000 (10%) result in death [3] .
Nm is classified based on the chemical composition of the polysaccharide capsule.
There are 13 antigenically distinct serogroups; A, B, C, D, E-29, H, I, K, L, W-135, X, Y, and Z, of which six; A, B, C, W-135, X, and Y, cause virtually all invasive diseases [4] . The incidence of IMD may be up to 100 per 100,000 in an epidemic season in the African meningitis belt but endemic disease incidence tends to lie between 1 to 2 per 100,000 in UK, Europe, and Australia and 0.5 to 1.5 per 100,000 in the US [5] . The relative contribution of each serogroup to all IMD is dynamic and varies both geographically and temporally [5, 6] . The majority of invasive diseases in Africa are caused by serogroup A, and in most developed countries, serogroups B and C. Over the past decade, serogroup Y has become a major contributor to IMD in the US and is steadily increasing in importance in some Nordic countries [5, 7] . Recently, there also has been a significant increase in the incidence of serogroup W-135 in both South Africa and South America, demonstrating the propensity for strain dominance to change in unpredictable ways [8, 9] . The frequency of IMD also varies by age. The highest burden of Nm is in young children, especially infants, and a second smaller peak occurs in adolescence.
The routine use of polysaccharide-protein conjugate vaccines in infant schedules has resulted in dramatic country-specific declines in disease burden and mortality caused by these encapsulated bacteria [10] [11] [12] . Hib, once the major causative organism of bacterial meningitis in children under 5 years of age, has been practically eliminated by routine use in many countries [13] . The control of IMD, however, has been more challenging.
In the late 1990s, the emergence of a hypervirulent meningococcal serogroup C [23] .
The Vaccine
HibMenCY-TT is a combination of three discrete polysaccharide-protein conjugates. HibMenCY-TT is supplied as a single-dose vial of lyophilized vaccine to be reconstituted with the accompanying vial of saline diluent [24] .
Mechanism of Action
Due to the low incidence of meningococcal disease, as for other novel meningococcal vaccines, efficacy trials of HibMenCY-TT were impractical and effectiveness was inferred based on demonstration of immunogenicity and achievement of presumed correlates of protection [25] . Serum bactericidal activity (SBA) is a functional assay that measures killing of Nm by antibodies contained in the patient's serum in the presence of complement. The complement source may be human (hSBA) or rabbit (rSBA). For hSBA, a titer of C4 is the accepted correlate of protection for serogroup C based on clinical effectiveness [26] . For rSBA, a more conservative titer of C8 has been found to be most consistent with clinical efficacy of conjugate vaccines against serogroup C disease [25, 27] . Of note, this low bactericidal titer (with rabbit complement) does not necessarily indicate that bactericidal activity is the mechanism of immune protection (e.g., it may be a marker for an alternative mechanism such as human complementenhanced opsonic antibody [28] ). For serogroup Y, no true correlate of protection exists and the same hSBA and rSBA titers as for MenC have been accepted as surrogates of protection [27] .
Due to the virtual elimination of Hib disease Finland, it has been widely accepted that an anti-PRP antibody concentration of C0.15 lg/ ml is adequate to confer short-term protection,
and an anti-PRP concentration of C1.0 lg/ml is required for long-term protection (or protection for the following 12 months) [29, 30] . MenACWY-PS at 3-5 years of age [33] . A second phase of this study compared the immunogenicity and safety of a fourth dose of HibMenCY-TT compared with Hib-TT in a subset of infants at 12-15 months who had previously been primed with three doses of HibMenCY-TT or Hib-TT, respectively [34] . A third paper published data from these two clinical trials on the immune response to antigens administered concomitantly with HibMenCY-TT both at priming and at the fourth booster dose [35] . The US infant study providing evidence of immune memory [34] .
CLINICAL TRIAL DATA
There was no immune interference to any concomitantly administered antigens with HibMenCY-TT in infancy (Streptococcus pneumoniae serotypes contained in PCV7 or diphtheria, tetanus, pertussis, hepatitis B, and poliovirus antigens contained in DTPa-HBV-IPV) or in anti-pneumococcal antibody concentrations after the fourth HibMenCY-TT dose [35] .
A large phase II/safety and immunogenicity study undertaken in Australia randomized more than 1,100 participants to receive three doses of HibMenCY-TT at 2, 4, and 6 months compared with Hib-TT ? MenC-CRM or Hib-TT alone [36] . At 12-15 months, a fourth dose of [36] . Importantly, this study also assessed the immunogenicity after two doses of HibMenCY-TT in infancy and found rSBA titers C8 against MenC and Y in 94% and 83%, respectively, suggesting protection from serogroups C and Y meningococcal disease may be afforded as early as 5 months of age with this schedule. However, for all three HibMenCY antigens a 6-month dose still has immunologic value suggested by marked rises in anti-PRP GMC and MenC and Y GMTs after the third dose [36] .
Phase III Clinical Trials
The phase III/pivotal clinical trial evaluated the safety, immunogenicity, and lot-to-lot consistency of HibMenCY-TT in 4,180 infants in three cohorts, across 91 centers in three countries [37] . Cohort one included only US infants for immunogenicity and safety (n = 991), cohort two included children in the US, Australia, and Mexico for safety endpoints only (n = 2,989), and cohort three, Mexican infants for immunogenicity and safety (n = 200). As there was no licensed MenC vaccine available to use as a control in this age group in the US, all infants were randomized to receive three doses of HibMenCY-TT or Hib-TT at 2, 4, and 6 months and HibMenCY-TT or Hib-OMP at 12-15 months (monovalent MenC was administered to Australian children after the study completion in accordance with their National Immunisation Program) [37] .
Immunogenicity Against Nm Serogroups C and Y
The proportion of participants with hSBA titers C8 was 99% and 96% after the third dose and 99% after dose 4, for both MenC and MenY, respectively. MenC and Y hSBA titers increased 12-fold from pre-to post-fourth dose levels [37] .
Immunogenicity Against Hib
The proportion of participants with anti-PRP antibody concentrations C1.0 lg/ml was noninferior (96% in the HibMenCY-TT group vs. 91% the Hib-TT group post dose 3 and 99% post dose 4 for both HibMenCY-TT and control
Hib-OMP groups) [37] . As in phase II studies, PRP GMCs were significantly higher after three doses of HibMenCY-TT than Hib-TT [33, 36, 37] and also pre-dose 4 and 1 month after the fourth dose compared with after monovalent Hib vaccine [34, 36, 37] . Further, a booster response to the fourth dose of HibMenCY-TT was observed [34, 36] .
Concomitant Vaccine Administration
Co-administration of HibMenCY-TT with DTPa-HBV-IPV and PVC7 at 2, 4, and 6 months did not cause immune interference to any concomitantly administered antigens [35] .
Further, a pooled analysis of 1,257 toddlers found non inferiority of immune responses to measles, mumps and rubella, and varicella antigens when administered concomitantly with a fourth dose of HibMenCY-TT compared to Hib-OMP vaccine at 12-15 months of age [38] .
Safety and Tolerability
Despite the addition of MenC and Y antigens, the reactogenicity of HibMenCY-TT does not differ from that associated with administration of Hib-TT vaccine [33, 36, 37] . A pooled safety analysis that included more than 8,500
participants from two primary vaccination and two-fourth dose phase III clinical trials found the incidence of serious adverse events, adverse events and solicited local and general systemic symptoms were similar following HibMenCY-TT and licensed Hib vaccines [39] .
Rates of pain at the injection site and irritability were significantly lower following
HibMenCY-TT than commercially available Hib vaccines [39] .
LICENSURE, SCHEDULE, AND RECOMMENDATIONS FOR USE
On June 14, 2012, HibMenCY-TT became the first meningococcal vaccine licensed by the FDA for use in infants, age 2-8 months in the US. It was approved for use in children age 6 weeks to 18 months for the prevention of invasive Hib and serogroup C and Y meningococcal disease [24] .
Recommendations for Use
Phase population), approximately 60% of disease in that age group was caused by serogroup B.
Further, the highest incidence in children aged less than 5 years is in those in the first 6 months of life when most infants would still be too young to have received two or three doses of vaccine required for adequate protection [40] . Cost-effectiveness estimates are unfavorable. In October 2011, the CDC calculated the cost per quality-adjusted life year (QALY) averted for infant meningococcal vaccination in the US to be $3.6 million per case [41] . Accordingly, the ACIP concluded that the present low burden of disease, combined with the lack of efficacy of conjugate meningococcal vaccines against serogroup B, limits the potential impact of a routine infant meningococcal program in the US [40] . While the report did not raise the issues of HibMenCY-TT may be given concomitantly with other routine infant vaccines, including 7-or 13-valent pneumococcal conjugate vaccines [33, 35, 37, 40] . It may also be given concomitantly with MMR and varicella vaccine [37] . As HibMenCY-TT incudes Hib, it should not be administered concomitantly with other Hib-containing vaccines. Infect Dis Ther (2013) 2:1-13 11
